ESR1 and triple-negative breast carcinoma: Patients with triple-negative breast cancers (TNBC; estrogen receptor-, progesterone receptor-, and HER2-negative) typically have a poor prognosis; thus, there is an increasing need for new therapeutic approaches that target TNBC [45].